These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29057047)

  • 1. Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.
    Staben LR; Yu SF; Chen J; Yan G; Xu Z; Del Rosario G; Lau JT; Liu L; Guo J; Zheng B; Cruz-Chuh JD; Lee BC; Ohri R; Cai W; Zhou H; Kozak KR; Xu K; Lewis Phillips GD; Lu J; Wai J; Polson AG; Pillow TH
    ACS Med Chem Lett; 2017 Oct; 8(10):1037-1041. PubMed ID: 29057047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, and Cytotoxic Evaluation of Novel Tubulysin Analogues as ADC Payloads.
    Leverett CA; Sukuru SC; Vetelino BC; Musto S; Parris K; Pandit J; Loganzo F; Varghese AH; Bai G; Liu B; Liu D; Hudson S; Doppalapudi VR; Stock J; O'Donnell CJ; Subramanyam C
    ACS Med Chem Lett; 2016 Nov; 7(11):999-1004. PubMed ID: 27882198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucuronide-Linked Antibody-Tubulysin Conjugates Display Activity in MDR
    Burke PJ; Hamilton JZ; Pires TA; Lai HWH; Leiske CI; Emmerton KK; Waight AB; Senter PD; Lyon RP; Jeffrey SC
    Mol Cancer Ther; 2018 Aug; 17(8):1752-1760. PubMed ID: 29866744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving Antibody-Tubulysin Conjugates through Linker Chemistry and Site-Specific Conjugation.
    Hamilton JZ; Pires TA; Mitchell JA; Cochran JH; Emmerton KK; Zaval M; Stone IJ; Anderson ME; Jin S; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
    ChemMedChem; 2021 Apr; 16(7):1077-1081. PubMed ID: 33369163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Access to Potent Anticancer Tubulysins and Linker-Functionalized Payloads Via an All-On-Resin Strategy.
    Ricardo MG; Llanes D; Rennert R; Jänicke P; Rivera DG; Wessjohann LA
    Chemistry; 2024 Jul; 30(42):e202401943. PubMed ID: 38771268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of Novel Quaternary Ammonium Linkers for Antibody-Drug Conjugates.
    Burke PJ; Hamilton JZ; Pires TA; Setter JR; Hunter JH; Cochran JH; Waight AB; Gordon KA; Toki BE; Emmerton KK; Zeng W; Stone IJ; Senter PD; Lyon RP; Jeffrey SC
    Mol Cancer Ther; 2016 May; 15(5):938-45. PubMed ID: 26944920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.
    Tumey LN; Leverett CA; Vetelino B; Li F; Rago B; Han X; Loganzo F; Musto S; Bai G; Sukuru SC; Graziani EI; Puthenveetil S; Casavant J; Ratnayake A; Marquette K; Hudson S; Doppalapudi VR; Stock J; Tchistiakova L; Bessire AJ; Clark T; Lucas J; Hosselet C; O'Donnell CJ; Subramanyam C
    ACS Med Chem Lett; 2016 Nov; 7(11):977-982. PubMed ID: 27882194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of tubulysin analogues.
    Courter JR; Hamilton JZ; Hendrick NR; Zaval M; Waight AB; Lyon RP; Senter PD; Jeffrey SC; Burke PJ
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127241. PubMed ID: 32527543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of novel ADCs: conjugation of tubulysin analogues to trastuzumab monitored by dual radiolabeling.
    Cohen R; Vugts DJ; Visser GW; Stigter-van Walsum M; Bolijn M; Spiga M; Lazzari P; Shankar S; Sani M; Zanda M; van Dongen GA
    Cancer Res; 2014 Oct; 74(20):5700-10. PubMed ID: 25145670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
    Salomon PL; Singh R
    Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex LC-MS/MS Assays for Clinical Bioanalysis of MEDI4276, an Antibody-Drug Conjugate of Tubulysin Analogue Attached via Cleavable Linker to a Biparatopic Humanized Antibody against HER-2.
    Faria M; Peay M; Lam B; Ma E; Yuan M; Waldron M; Mylott WR; Liang M; Rosenbaum AI
    Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
    Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
    Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody-Drug Conjugates, Insights into Structure-Activity Relationships, and Tubulysin-Tubulin Binding Derived from X-ray Crystallographic Analysis.
    Nicolaou KC; Pan S; Pulukuri KK; Ye Q; Rigol S; Erande RD; Vourloumis D; Nocek BP; Munneke S; Lyssikatos J; Valdiosera A; Gu C; Lin B; Sarvaiaya H; Trinidad J; Sandoval J; Lee C; Hammond M; Aujay M; Taylor N; Pysz M; Purcell JW; Gavrilyuk J
    J Org Chem; 2021 Feb; 86(4):3377-3421. PubMed ID: 33544599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
    Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
    Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.
    Puthenveetil S; Loganzo F; He H; Dirico K; Green M; Teske J; Musto S; Clark T; Rago B; Koehn F; Veneziale R; Falahaptisheh H; Han X; Barletta F; Lucas J; Subramanyam C; O'Donnell CJ; Tumey LN; Sapra P; Gerber HP; Ma D; Graziani EI
    Bioconjug Chem; 2016 Aug; 27(8):1880-8. PubMed ID: 27412791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.
    Thompson P; Fleming R; Bezabeh B; Huang F; Mao S; Chen C; Harper J; Zhong H; Gao X; Yu XQ; Hinrichs MJ; Reed M; Kamal A; Strout P; Cho S; Woods R; Hollingsworth RE; Dixit R; Wu H; Gao C; Dimasi N
    J Control Release; 2016 Aug; 236():100-16. PubMed ID: 27327768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo structural activity and optimization studies of folate-tubulysin conjugates.
    Reddy JA; Dorton R; Dawson A; Vetzel M; Parker N; Nicoson JS; Westrick E; Klein PJ; Wang Y; Vlahov IR; Leamon CP
    Mol Pharm; 2009; 6(5):1518-25. PubMed ID: 19630399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Resistance to Antibody-Drug Conjugates.
    Collins DM; Bossenmaier B; Kollmorgen G; Niederfellner G
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30897808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating Antibody-Drug Conjugate Payload Metabolism by Conjugation Site and Linker Modification.
    Su D; Kozak KR; Sadowsky J; Yu SF; Fourie-O'Donohue A; Nelson C; Vandlen R; Ohri R; Liu L; Ng C; He J; Davis H; Lau J; Del Rosario G; Cosino E; Cruz-Chuh JD; Ma Y; Zhang D; Darwish M; Cai W; Chen C; Zhou H; Lu J; Liu Y; Kaur S; Xu K; Pillow TH
    Bioconjug Chem; 2018 Apr; 29(4):1155-1167. PubMed ID: 29481745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.